Engineered sgrna design and preparation method

By adding adenine-rich ribonucleotide sequences to the 3' end of the sgRNA and performing capping enzyme modification, the problems of poor stability of transcriptional sgRNA and limiting chemical synthesis in vitro are solved, and efficient gene editing is achieved.

WO2024244000A1PCT designated stage expired Publication Date: 2024-12-05UBRIGENE (MA) BIOSCIENCES INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/098054
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-06-02
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

In the prior art, sgRNA prepared by in vitro transcription has poor stability, resulting in low gene editing efficiency and limited chemical synthesis length, making it impossible to achieve the upper fidelity limit of longer sequences.

Method used

Add adenine ribonucleotide-rich sequences at the 3' end of the sgRNA, at least 20 ribonucleotides in length, and improve RNA stability and gene editing efficiency through capping and tailing enzyme modification.

Benefits of technology

It significantly improves the stability and gene editing efficiency of sgRNA, reduces production costs, simplifies the process, and achieves efficient gene editing of longer sequences.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2023098054-FTAPPB-I100001
    Figure PCTCN2023098054-FTAPPB-I100001
  • Figure PCTCN2023098054-FTAPPB-I100002
    Figure PCTCN2023098054-FTAPPB-I100002
  • Figure PCTCN2023098054-FTAPPB-I100003
    Figure PCTCN2023098054-FTAPPB-I100003
Patent Text Reader

Abstract

Provided in the present invention are a DNA-targeting RNA and the use thereof in gene editing. The RNA contains a single guide RNA (sgRNA) and a ribonucleotide sequence rich in adenine ribonucleotide. Further provided is a method for improving the efficiency of sgRNA-mediated gene editing, the method comprising adding a ribonucleotide sequence rich in adenine ribonucleotide to the 3' end of an sgRNA.
Need to check novelty before this filing date? Find Prior Art

Description

A method for designing and preparing engineered sgRNA Technical Field

[0001] The present invention relates to the field of gene editing, and in particular to an engineered single guide RNA (sgRNA). Background Art

[0002] Clustered regularly interspaced short palindromic repeats (CRISPR) technology is a two-component gene editing system in which effector proteins induce gene editing with the help of gene-targeting single-guide RNA (sgRNA) (Wiedenheft, B. et al. (2012) RNA-guided genetic silencing systems in bacteria and archaea. Nature 482, 331-338). The sgRNA structure includes CRISPR RNA (crRNA), trans-activating crRNA (trans-activating crRNA, tracrRNA) and tetraloop, with a length of 97-103 nucleotides (Basila, M. et al. (2017) Minimal 20-O-methyl phosphorothioate linkage modification pattern of synthetic guide RNAs for increased stability and efficient CRISPR-Cas9 gene editing avoiding cellular toxicity. PLoS One 12, e0188593).

[0003] sgRNA can be produced by chemical synthesis (Wang, W. et al. (2018) Bacteriophage T7 transcription system: an enabling tool in synthetic biology. Biotechnol. Adv. 36, 2129–2137) or in vitro transcription. Chemical synthesis of sgRNA can quickly provide sufficient quantity and purity of the desired sgRNA, but technically, chemical synthesis of lengthy RNAs is not feasible. The length of chemically synthesized sgRNA (102 nt) is close to the upper limit of sequence fidelity that can be achieved by chemical synthesis technology (Zetsche, B. et al. (2015) Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell 163, 759–77125).

[0004] In vitro transcription can prepare longer sgRNAs, and is easy to scale up and produce with high sequence fidelity. However, since base and structure modifications cannot be performed during the in vitro transcription process, sgRNAs are less stable and easily degraded by nucleases, resulting in low gene editing efficiency of nucleases guided by sgRNAs of the same sequence prepared by in vitro transcription (Hu Z. et al. Customized one-step preparation of sgRNA transcription templates via overlapping PCR Using short primers and its application in vitro and in vivo gene editing[J]. Cell, Bioscience, 2019, 9).

[0005] sgRNAs can be engineered in a variety of ways, including chemical modification, altering the length of the spacer sequence, modifying the spacer or scaffold sequence, modifying the DNA sequence, and replacing parts of the RNA sequence with DNA. Chemical modification can only be used during the chemical synthesis of sgRNA, and the length of chemical synthesis is limited to 110 nucleotides. Changing the length of the spacer sequence can improve the specificity of sgRNA-guided gene editing, but it does not improve the stability of the sgRNA or the efficiency of gene editing. Modification of the spacer or scaffold sequence can improve the binding ability of the sgRNA to the Cas9 protease, but it does not improve the stability of the sgRNA. Modification and replacement of the DNA sequence are technically complex and the cost of sgRNA preparation is high.

[0006] Therefore, it is necessary to be able to prepare a large amount of sgRNA with high gene editing efficiency through in vitro transcription.

[0007] To study RNA stability, we first attempted to modify the 5' and 3' ends of sgRNA using capping and tailing enzymes. The results showed that compared to unmodified sgRNA, sgRNA modified with capping and tailing enzymes significantly improved gene editing efficiency (Figure 4A, comparison of results in lanes 2 and 3; Figure 4B, comparison of results in lanes 2 and 3). However, due to the high cost of tailing and capping enzymes and the uncertainty of the number of poly(A) tails, the production of sgRNA is costly, complex, and has low sgRNA sequence uniformity.

[0008] In a first aspect, the present invention provides a DNA-targeting RNA comprising an sgRNA and a sequence of greater than 20 ribonucleotides rich in adenine ribonucleotides (A) at the 3' end. Preferably, the length of the ribonucleotide sequence rich in adenine ribonucleotides (A) is at least 20 ribonucleotides, wherein the content of A in the ribonucleotide sequence is at least 60%, and more preferably, is selected from SEQ ID NOs: 13, 20, and 21.

[0009] In one embodiment, the sgRNA comprises, from 5' to 3' direction, a ribonucleotide sequence that specifically targets a DNA sequence and a CRISPR effector protein-binding portion. In particular, the ribonucleotide sequence that targets the DNA sequence is 18-25 ribonucleotides in length and is preferably 100% complementary to the target sequence in the DNA, and / or the protein-binding portion comprises two at least partially complementary ribonucleotide segments that hybridize to form a double-stranded RNA (dsRNA) duplex.

[0010] In a second aspect, the present invention provides an isolated nucleic acid encoding the DNA-targeting RNA of the first aspect.

[0011] In a third aspect, the present invention provides a construct comprising the nucleic acid of the second aspect.

[0012] In a fourth aspect, the present invention provides a method for producing a DNA-targeting RNA according to the first aspect, comprising: (a) providing a nucleic acid encoding the DNA-targeting RNA, such as the nucleic acid according to the second aspect; and (b) transcribing the nucleic acid in vitro to produce RNA, and (c) optionally isolating and / or purifying the produced RNA. In particular, the nucleic acid is obtained by PCR amplification.

[0013] In a fifth aspect, the present invention provides a method for improving the efficiency of sgRNA-mediated gene editing, comprising adding a ribonucleotide sequence rich in adenine ribonucleotides (A) to the 3' end of the sgRNA, wherein the ribonucleotide sequence is at least 20 ribonucleotides in length, wherein the content of A in the ribonucleotide sequence is at least 60%. In particular, the ribonucleotide sequence rich in adenine ribonucleotides (A) is selected from the group consisting of SEQ ID NOs: 13, 20, and 21.

[0014] In a sixth aspect, the present invention provides a kit comprising:

[0015] - a template primer nucleic acid comprising a nucleic acid sequence encoding a CRISPR effector protein binding portion; and

[0016] - a first primer comprising, from 5' to 3' direction, a sequence complementary to the sequence shown in SEQ ID NO: 13, 20 or 21 and a sequence complementary to a portion of the 3' end of the template primer nucleic acid,

[0017] - Optionally comprises a second primer encoding, from 5' to 3' direction, a promoter, a sequence corresponding to a ribonucleotide sequence of a specific targeting DNA sequence, and a sequence corresponding to a portion of the 5' end of the CRISPR effector protein binding portion.

[0018] In a seventh aspect, the present invention provides a gene editing method, comprising using the DNA-targeting RNA of the first aspect, the nucleic acid of the second aspect, or the construct of the third aspect.

[0019] In an eighth aspect, the present invention provides use of the DNA-targeting RNA of the first aspect, the nucleic acid of the second aspect, or the construct of the third aspect for gene editing. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1: Flowchart of sgRNA preparation by PCR method.

[0021] Figure 2: Different types of sgRNAs guide Cas9 protein to cleave DNA fragments in vitro. The DNA fragment size is approximately 926 bp, and the fragment sizes after enzyme digestion are approximately 516 bp and 410 bp, respectively. Lanes 1 and 7 are DNA markers; lane 2 is the target DNA fragment; lane 3 shows chemically synthesized sgRNA guiding Cas9 protein to cleave the target DNA fragment in vitro, where the ends of the sgRNA are modified with 2'-O-methyl and phosphorothioate, respectively (SEQ ID NO: 3); lane 4 shows in vitro transcribed sgRNA guiding Cas9 protein to cleave the target DNA fragment in vitro, where the 3' end of the sgRNA is modified with a poly(A) tail; lanes 5 and 6 show in vitro transcribed sgRNA guiding Cas9 protein to cleave the target DNA fragment in vitro, where the sgRNA is not modified in any way.

[0022] Figure 3: Different types of sgRNAs guide Cas9 protein to cleave DNA fragments in vitro. The DNA fragment size is approximately 900 bp, and the fragment sizes after enzyme digestion are approximately 500+ bp and 400 bp, respectively. Lanes 1 and 6 are DNA markers; lane 2 is the target DNA fragment; lane 3 shows a chemically synthesized sgRNA guiding Cas9 protein to cleave the target DNA fragment in vitro, where the ends of the sgRNA are 2'-O-methyl modified and phosphorothioate modified, respectively (SEQ ID NO: 3); lane 4 shows an in vitro transcribed sgRNA guiding Cas9 protein to cleave the target DNA fragment in vitro, where the 3' end of the sgRNA has a fixed sequence (the fixed sequence is shown in SEQ ID NO: 13); lane 5 shows an in vitro transcribed sgRNA guiding Cas9 protein to cleave the target DNA fragment in vitro, where the 3' end of the sgRNA has a fixed sequence (the fixed sequence is shown in SEQ ID NO: 13) and the 5' end of the sgRNA has a cap.

[0023] Figure 4: Detection of homologous recombination of the target sequence after different types of sgRNA guide Cas9 protein for intracellular gene editing. This experimental process first uses different types of sgRNA to guide Cas9 protein for intracellular gene editing and simultaneously adds the target DNA sequence for insertion into the genome. The target DNA sequence is inserted into the genome through homologous recombination repair. The cells are then cultured for 72 hours, the cell genome is extracted, and finally, whether homologous recombination has occurred in the cell is determined by whether the sequence integrated into the genome can be amplified. The amplification primers are located at both ends of the left homology arm and the right homology arm respectively. The forward primer sequence (SEQ ID NO: 9) for verifying homologous recombination of the left homology arm is located in the genome on the left side of the homology arm, and the reverse primer sequence (SEQ ID NO: 11) for verifying homologous recombination of the left homology arm is located in the inserted gene sequence; the forward primer sequence (SEQ ID NO: 12) for verifying homologous recombination of the right homology arm is located in the genome on the right side of the homology arm, and the reverse primer sequence (SEQ ID NO: 10) for verifying homologous recombination of the right homology arm is located in the inserted gene sequence. Figure 4A shows the sequence amplification after homologous recombination near the left homologous arm, wherein the amplified sequence fragment size is 1304 bp; Figure 4B shows the sequence amplification after homologous recombination near the right homologous arm, wherein the amplified sequence fragment size is 1321 bp; Lane 1 is a DNA Marker; Lane 2 is a DNA fragment amplified after homologous recombination guided by sgRNA (unmodified) prepared by in vitro transcription and Cas9 protein; Lane 3 is a DNA fragment amplified after homologous recombination guided by sgRNA (5' end capping and 3' end tailing modification) prepared by in vitro transcription and Cas9 protein; Lane 4 is a DNA fragment amplified after homologous recombination guided by sgRNA (3' end fixed sequence modification) prepared by in vitro transcription and Cas9 protein; Lane 5 is a DNA fragment amplified after homologous recombination guided by sgRNA (5' end capping and 3' end fixed sequence modification) prepared by in vitro transcription. ) and Cas9 protein-guided homologous recombination; Lane 6 is the DNA fragment amplified after homologous recombination guided by chemically synthesized sgRNA (2'-O-methyl modification and phosphorothioate modification at the 5' and 3' ends) and Cas9 protein; Lane 7 is the DNA fragment amplified after homologous recombination guided by only chemically synthesized sgRNA (2'-O-methyl modification and phosphorothioate modification at the 5' and 3' ends), and this experimental group serves as the negative control group; Lane 8 is the DNA fragment amplified by cells without gene editing, and this experimental group serves as the negative control group.

[0024] Figure 5: Optimizing the 3' end of sgRNA to increase the sequence length. After successful gene editing, the NeonGreen-teLuciferase expression element in the stable cell line 293T-GL, which was originally capable of expressing NeonGreen-teLuciferase, was edited and replaced, and luciferase was no longer expressed. The previously expressed luciferase protein also gradually decreased to the background level within 1 week. Therefore, by detecting the residual luciferase activity 1 week after gene editing, the relative efficiency of gene editing mediated by different sgRNAs (SEQ ID NO: 14-19) can be compared. The results in Figure 5 show that the effect is better when the sequence added to the 3' end is more than 20 ribonucleotide residues, among which NG20-sgRNA has the best effect. (**, p<0.01) DETAILED DESCRIPTION

[0025] Unless otherwise indicated or the context is clear, the abbreviations used herein have their conventional meanings in the fields of chemistry and biology, and all technical and scientific terms used in the present invention have the same meanings as those commonly understood by those skilled in the art. Experimental methods not specifically described in the present invention are carried out according to the specific methods in the book "Molecular Cloning Laboratory Manual" (4th edition) by J. Sambrook, or in accordance with the instructions of the relevant products. The biological reagents used in the present invention can be obtained from commercial channels unless otherwise specified. Those skilled in the art can make various changes, modifications and substitutions without departing from the spirit of the present invention.

[0026] As used herein, the terms "peptide," "polypeptide," and "protein" are used interchangeably and are defined as biomolecules composed of amino acid residues linked by peptide bonds.

[0027] As used herein, the terms "nucleotide sequence," "polynucleotide," "nucleic acid," and "nucleic acid sequence" are used interchangeably to refer to a macromolecule composed of multiple nucleotides linked by 3'-5'-phosphodiester bonds, wherein the nucleotides include ribonucleotides and deoxyribonucleotides. Unless otherwise specified or as can be determined from the context, nucleic acids herein include, but are not limited to, single-stranded, double-stranded, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, and the like.

[0028] Unless otherwise indicated, nucleic acid (including DNA and RNA) sequences are referred to herein in the 5′ to 3′ direction from left to right; amino acid sequences are referred to in the amino (N) to carboxyl (C) direction from left (upstream) to right (downstream).

[0029] As used herein, the terms "deoxyribonucleic acid sequence," "deoxyribonucleotide sequence," "polydeoxyribonucleotide," and "DNA" are used interchangeably and refer to deoxyribonucleic acid, a linear or circular polymer whose backbone is formed by deoxyribonucleotides (deoxyadenine nucleotides (A), deoxyguanine nucleotides (G), deoxycytosine nucleotides (C), and / or deoxythymidine nucleotides (T)) linked by 3', 5'-phosphodiester bonds, and may be single-stranded or double-stranded, linear or circular. DNA may contain suitable modifications known in the art, such as methylation, phosphorothioate, and the like.

[0030] As used herein, the terms "ribonucleic acid sequence," "ribonucleotide sequence," "polyribonucleotide," and "RNA" are used interchangeably and refer to ribonucleic acid, a linear macromolecule whose backbone is composed of ribonucleotides (adenine nucleotides (A), guanine nucleotides (G), cytosine nucleotides (C), and / or uracil nucleotides (U)) polymerized via phosphodiester bonds. Unless otherwise specified or inferred from the context, reference to RNA refers to a single-stranded RNA molecule. The single-stranded RNA molecule may have a partially double-stranded structure (e.g., a stem-loop structure), and after denaturation, the RNA molecule is a single-stranded nucleotide chain.

[0031] As used herein, "complementary" refers to a sequence that is complementary to a given sequence in the opposite orientation (i.e., 5'-3' / 3'-5') using Watson-Crick base pairing, i.e., AT / AU or GC, to form a double strand. For example, 5'-ATGC-3' and 5'-GCAT-3' are complementary sequences to each other. The length of the complementary sequence used herein can be any suitable length, preferably 10-30 nucleotides, more preferably 15-30 nucleotides, and even more preferably 20-30 nucleotides.

[0032] As used herein, the term "DNA sequence encoding" an RNA is a DNA nucleic acid sequence that is transcribed into the RNA. The DNA nucleic acid can encode an mRNA, tRNA, rRNA, or a DNA-targeting RNA as described herein.

[0033] As used herein, "gRNA" and "guide RNA" are used interchangeably and refer to an RNA molecule that can form a complex with a CRISPR effector protein and can target the complex to a target sequence due to a certain complementarity with the target sequence. For example, in a Cas9-based gene editing system, gRNA is generally composed of crRNA and tracrRNA molecules that are partially complementary to form a complex, wherein the crRNA comprises a sequence that is sufficiently complementary to the target sequence so as to hybridize with the target sequence and guide the CRISPR complex (Cas9+crRNA+tracrRNA) to specifically bind to the target sequence. It is known in the art that a single guide RNA (sgRNA) can be designed that contains features of both crRNA and tracrRNA.

[0034] As used herein, the term "single guide RNA" or "sgRNA" refers to a single RNA molecule that is capable of forming a complex with a CRISPR effector protein and targeting the complex to a target sequence (e.g., a specific sequence in a DNA sequence to be edited) due to a nucleotide sequence (such as a spacer sequence as described herein) having a certain degree of complementarity with the target sequence. For example, an sgRNA can include a ribonucleotide sequence that specifically targets a DNA sequence and a CRISPR effector protein-binding portion that includes two complementary sequences capable of forming an RNA duplex. Designing a suitable sgRNA based on the CRISPR nuclease used and the target sequence to be edited is within the capabilities of those skilled in the art, for example, see: Wang, Y. et al. Simultaneous editing of three homoeoalleles in hexaploid bread wheat confers heritable resistance to powdery mildew. Nat. Biotechnol. 32, 947-951 (2014); Shan, Q. et al. Targeted genome modification of crop plants using a CRISPR-Cas system. Nat. Biotechnol. 31, 686-688 (2013); Liang, Z. et al. Targeted mutagenesis in Zea mays using TALENs and the CRISPR / Cas system. J Genet Genomics. 41, 63–68 (2014).

[0035] As used herein, the term "CRISPR effector protein" generally refers to a nuclease present in a naturally occurring CRISPR system, as well as modified forms thereof, variants thereof, catalytically active fragments thereof, and the like. The term encompasses any effector protein or functional variant thereof that is capable of achieving gene editing in a cell based on a CRISPR system. CRISPR effector proteins can recognize, bind to, and / or cut target nucleic acid structures by interacting with sgRNA. In some embodiments, the CRISPR effector protein and its functional variant have double-stranded cleavage activity, i.e., the ability to form double-strand breaks (DSBs) in a target sequence.

[0036] The gene editing generally results in the deletion of one or more nucleotides in the target sequence, preferably the deletion of multiple consecutive nucleotides. The type and length of the deletion depends on the double-strand break (DSB) position caused by the CRISPR nuclease and the number and position of cytosine (C) bases present in the target sequence or its complementary sequence. In some embodiments, the length of the deletion does not exceed the length of the target sequence. For example, the deletion can be about 1-25 nucleotides, such as 10-25 nucleotides, such as 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides.

[0037] Examples of “CRISPR effector proteins” are, for example, Cas9 nucleases or active variants thereof (e.g., proteins comprising an active DNA cleavage domain of Cas9 and a gRNA binding domain of Cas9). “Cas9 nuclease” and “Cas9” are used interchangeably herein and are components of the CRISPR / Cas (clustered regularly interspaced short palindromic repeats and related systems) genome editing system that can target and cut DNA target sequences to form DNA double-strand breaks (DSBs) under the guidance of guide RNA. The Cas9 nuclease can be a Cas9 nuclease from a different species, such as spCas9 from Streptococcus pyogenes (S. pyogenes) or SaCas9 derived from Staphylococcus aureus (S. aureus).

[0038] Examples of “CRISPR effector proteins” may also include Cpf1 nuclease or variants thereof, which may be from different species, such as Cpf1 nuclease from Francisella novicida U112, Acidaminococcus sp. BV3L6, and Lachnospiraceae bacterium ND2006.

[0039] As used herein, a "target sequence" is a sequence that is complementary or identical (depending on the CRISPR nuclease) to the approximately 20 ribonucleotide guide (spacer) sequence contained in the sgRNA. The sgRNA targets the target sequence by base pairing with the target sequence or its complementary strand.

[0040] In a first aspect, the present invention provides a DNA-targeting RNA comprising, from 5' to 3' direction, (i) a single guide RNA (sgRNA) and (ii) a ribonucleotide sequence rich in adenine ribonucleotides (A), wherein the adenine-rich ribonucleotide sequence is at least 20 ribonucleotides in length, wherein the content of A in the adenine-rich ribonucleotide sequence is at least 60%.

[0041] In one embodiment, the length of the adenine ribonucleotide-rich ribonucleotide sequence is 20-30, such as 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 ribonucleotides. Preferably, the length of the adenine ribonucleotide-rich ribonucleotide sequence is 20-25, 20-24, 20-23, such as 20, 21, 22, 23, 24 ribonucleotides. In a particularly preferred embodiment, the length of the adenine ribonucleotide-rich ribonucleotide sequence is 20 ribonucleotides.

[0042] In one embodiment, the content of A in the adenine ribonucleotide-rich ribonucleotide sequence is at least 70%, at least 75%, at least 80%, at least 90%, at least 95% or more. The content refers to the percentage of adenine ribonucleotides to the total ribonucleotides in the ribonucleotide sequence.

[0043] In one embodiment, the adenine ribonucleotide-rich ribonucleotide sequence is selected from SEQ ID NOs: 13, 20, and 21. In a particularly preferred embodiment, the adenine ribonucleotide-rich ribonucleotide sequence is shown in SEQ ID NO: 20.

[0044] In one embodiment, the 5' end of the adenine ribonucleotide-rich ribonucleotide sequence can be directly linked to the 3' end of the CRISPR effector protein binding portion or indirectly linked via any suitable means known in the art, such as a nucleotide linker, as long as the interaction between the CRISPR effector protein binding portion and the CRISPR effector protein is not significantly affected after the connection.

[0045] In one embodiment, the nucleotide linker can be about 3-30 nucleotides in length, for example, about 3-25, 3-20, 3-15, 3-10, 3-5, 5-25, 5-20, 5-15, 5-10, 10-25, 10-25, 10-20, 10-15, 15-25, 15-20, 20-25 nucleotides, such as about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 nucleotides in length.

[0046] Herein, the RNA-targeted DNA can be any DNA that is desired to be edited, such as a DNA molecule present in a unicellular eukaryote, a plant cell, an invertebrate cell, or a vertebrate cell.

[0047] As used herein, the term "sgRNA" refers to any sgRNA known and available in the art. In one embodiment, the sgRNA comprises a ribonucleotide sequence that specifically targets a target DNA sequence and a CRISPR effector protein binding portion from the 5' to 3' direction. In one embodiment, the sgRNA comprises a CRISPR RNA (crRNA) and a transactivating crRNA (tracrRNA) from the 5' to 3' direction.

[0048] In one embodiment, the length of the sgRNA herein can be about 80-120 ribonucleotides, for example, about 80-115, 80-110, 80-105, 80-100, 80-95, 80-90, 85-115, 85-110, 85-105, 85-100, 85-95, 85-90, 90-115, 90-110, 90-105, 90-100, 95-115, 95-110, 95-100 ribonucleotides, such as 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105 ribonucleotides.

[0049] As used herein, the ribonucleotide sequence that specifically targets a target DNA sequence refers to a ribonucleotide sequence that comprises a ribonucleotide sequence that is complementary to the target DNA sequence. sgRNA is therefore able to interact with the target DNA in a sequence-specific manner by hybridization (i.e., base pairing). Depending on the target DNA sequence, those skilled in the art can design the desired specific targeting sequence to achieve specific interaction with the target DNA.

[0050] In one embodiment, the length of the ribonucleotide sequence that specifically targets the target DNA sequence can be about 8-50 nucleotides, for example, about 8-45, 8-40, 8-35, 8-30, 8-25, 8-20, 8-15, 8-14, 8-13, 8-12, 8-11, 8-10, 9-45, 9-40, 9-35, 9-30, 9-25, 9-20, 9-15, 9-14, 9-13, 9-12, 9-11, 10-45, 10-40, 10-35, 10-30, 10-25, 10-20, 10-15, 10-14, 10-13, 10-12 nucleotides, for example, about 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 nucleotides. In one embodiment, the length of the ribonucleotide sequence that specifically targets a target DNA sequence may be about 20-23, such as 20, 21, 22 or 23 nucleotides.

[0051] In one embodiment, the ribonucleotide sequence that specifically targets the target DNA sequence is a ribonucleotide sequence that is at least partially complementary, preferably completely complementary, to the target DNA sequence, thereby enabling specific targeting of the target DNA sequence. In one embodiment, the ribonucleotide sequence that specifically targets the target DNA sequence is 18-25 ribonucleotides in length, for example, 18, 19, 20, 21, 22, 23, 24, or 25 ribonucleotides.

[0052] Herein, the CRISPR effector protein binding portion is a ribonucleotide structure capable of forming a complex with the CRISPR effector protein, whereby the CRISPR effector protein can be localized to the target DNA sequence through the targeting action of ribonucleotides that specifically target the target DNA sequence, thereby allowing subsequent genome editing (such as shown in CRISPR technology).

[0053] In one embodiment, the CRISPR effector protein binding portion comprises two at least partially complementary ribonucleotide fragments capable of forming a double-stranded RNA duplex. In one embodiment, the CRISPR effector protein binding portion comprises at least a portion of crRNA (i.e., the portion other than the ribonucleotide sequence that specifically targets the target DNA sequence) and tracrRNA, optionally comprising a tetraloop region.

[0054] In one embodiment, the crRNA and tracrRNA can be connected by a nucleotide linker and partial sequence hybridization forms a double-stranded RNA duplex, so as to form a stem-loop structure, so as to be able to interact with CRISPR effector protein (such as Cas9). In one embodiment, the length of the double-stranded RNA duplex can be about 6-50bp, for example, about 6-40, 6-30, 6-25, 6-20, 6-15, 8-40, 8-30, 8-25, 8-20 or 8-15bp, such as about 8-10, 10-15, 15-18, 18-20, 20-25, 25-30, 30-35, 35-40 or 40-50bp.

[0055] As used herein, crRNA comprises ribonucleotides that form half of a dsRNA duplex, and tracrRNA comprises ribonucleotides that form the other half of the dsRNA duplex. Thus, crRNA and tracrRNA complement and hybridize to form a dsRNA duplex that is part of the CRISPR effector protein binding site.

[0056] Various crRNAs and tracrRNAs are known or available in the art. For example, various crRNAs and tracrRNAs are shown in Figure 8 of CN107603976B in the form of corresponding complementary pairs. The sgRNA described herein may comprise any corresponding crRNA and tracrRNA pair.

[0057] In one embodiment, the protein binding portion may be about 8-100 ribonucleotides in length. For example, the protein binding portion may be about 10-100, 10-90, 10-80, 10-70, 10-60, 10-50, 10-40, 10-30, 10-20, 15-100, 15-90, 15-80, 15-70, 15-60, 15-50, 15-40, 15-30, 15-20, 20- 10, 15, 20, 25, 30, 35, 40 ribonucleotides.

[0058] In some embodiments, the CRISPR effector protein can be a nuclease selected from Cas3, Cas8a, Cas5, Cas8b, Cas8c, Cas10d, Cse1, Cse2, Csy1, Csy2, Csy3, GSU0054, Cas10, Csm2, Cmr5, Cas10, Csx11, Csx10, Csf1, Cas9, Csn2, Cas4, Cpf1, C2c1, C2c3 and C2c2, or functional variants of these nucleases.

[0059] The present inventors have discovered that, when the 3' end of the CRISPR effector protein binding portion is linked to a ribonucleic acid sequence as shown in SEQ ID NO: 13, 20, or 21, genome editing efficiency and target specificity can be improved, enabling efficient and safe gene editing. The 5' end of the ribonucleic acid sequence as shown in SEQ ID NO: 13, 20, or 21 can be directly linked to the 3' end of the CRISPR effector protein binding portion or indirectly linked via any suitable means known in the art, such as a nucleotide linker, as long as the linking does not significantly affect the interaction between the protein binding portion and the site-directed modifying polypeptide.

[0060] In a second aspect, the present invention provides an isolated nucleic acid encoding the RNA of the first aspect.

[0061] In particular, the nucleic acid is a DNA molecule that can be transcribed to produce the RNA. In one embodiment, the nucleic acid comprises a polynucleotide encoding the promoter, sgRNA, and the adenine ribonucleotide-rich ribonucleotide sequence described above.

[0062] In a third aspect, the present invention provides a construct comprising the nucleic acid of the second aspect.

[0063] In addition, the construct includes a vector such as an expression vector, wherein the construct includes the required elements for transcription and / or translation, such as a promoter, an enhancer, a transcription terminator, etc., from which RNA can be obtained by transcription. A variety of suitable expression vectors are known and available in the art.

[0064] Herein, the promoter can be any suitable promoter, particularly a eukaryotic promoter, including but not limited to T7 promoter, CMV immediate early promoter, SV40 promoter. In one embodiment, the T7 promoter comprises the sequence shown in nucleotides 1-21 of SEQ ID NO: 4.

[0065] In a fourth aspect, the present invention provides a method for producing the RNA of the first aspect, comprising: (a) providing a nucleic acid encoding the RNA; and (b) transcribing the nucleic acid in vitro to produce RNA, and optionally (c) isolating and / or purifying the produced RNA.

[0066] The nucleic acid encoding RNA can be provided by any suitable method, such as chemical synthesis or biological expression or amplification such as PCR. The nucleic acid can be RNA or DNA, preferably DNA.

[0067] As used herein, in vitro transcription refers to the process of synthesizing RNA from target DNA using transcription reagents such as RNA polymerase and other required ions or compounds in non-living cells or an extracellular environment.

[0068] The isolation and purification of RNA are well known to those skilled in the art and can be performed using any suitable method.

[0069] In one embodiment, the present invention provides a method for producing the RNA of the first aspect, comprising:

[0070] (i) providing a template primer nucleic acid comprising a binding portion corresponding to a CRISPR effector protein as described herein,

[0071] (ii) providing an upstream primer and a downstream primer, wherein the downstream primer comprises, from the 5′ to the 3′ direction, a sequence complementary to the sequence shown in SEQ ID NO: 13, 20, or 21 and a sequence complementary to a portion of the 3′ end sequence of the template primer nucleic acid, and the upstream primer comprises a nucleotide sequence corresponding to a ribonucleotide sequence that specifically targets the target DNA sequence and a portion of the 5′ end sequence of the template primer nucleic acid,

[0072] (iii) performing PCR amplification to obtain a template nucleic acid, preferably a template DNA,

[0073] (iv) performing in vitro transcription from the template nucleic acid to obtain RNA, and

[0074] (v) Optionally, isolating and purifying the obtained RNA.

[0075] In one embodiment, the upstream primer comprises a promoter sequence, a nucleotide sequence corresponding to a nucleotide sequence that specifically targets a target DNA sequence, and a partial sequence at the 5' end of the template primer nucleic acid.

[0076] As used herein, "a partial sequence corresponding to the 5' end of the template primer nucleic acid" and "a nucleotide sequence corresponding to a ribonucleotide sequence that specifically targets a target DNA sequence" mean that the nucleotide sequence is identical to the partial sequence of the 5' end of the template primer nucleic acid or the ribonucleotide sequence that specifically targets a target DNA sequence, except that T is used in DNA instead of U in RNA.

[0077] In one embodiment, the template primer nucleic acid comprises the DNA sequence shown in SEQ ID NO:6.

[0078] As used herein, the promoter may be any suitable promoter known in the art, such as those that can be used for in vitro transcription, such as T7 RNA polymerase promoter, T3 RNA polymerase promoter. In one embodiment, the promoter comprises the sequence shown in nucleotides 1-21 of SEQ ID NO: 4.

[0079] As used herein, the partial sequence at the 5' end of the template primer nucleic acid refers to a sequence located at the 5' end of the template primer nucleic acid, whereby the primer is complementary to the antisense strand of the template primer nucleic acid and hybridizes with the antisense strand after annealing of the template primer nucleic acid, thereby enabling amplification of the template primer nucleic acid by a suitable method, such as PCR.

[0080] As used herein, a sequence complementary to a portion of the sequence at the 3' end of a template primer nucleic acid refers to a sequence segment complementary to the sequence located at the 3' end of the template primer nucleic acid. Thus, the primer is complementary to the sense strand of the template primer nucleic acid and hybridizes to the sense strand after annealing of the template primer nucleic acid, thereby enabling amplification of the template primer nucleic acid by a suitable method, such as PCR.

[0081] The partial sequence at the 5' end or 3' end of the template primer nucleic acid or its complementary sequence can be any length suitable for use as a primer, for example, about 8-50 nucleotides, for example, about 8-45, 8-40, 8-35, 8-30, 8-25, 8-20, 8-15, 8-14, 8-13, 8-12, 8-11, 8-10, 9-45, 9-40, 9-35, 9-30, 9-25 , 9-20, 9-15, 9-14, 9-13, 9-12, 9-11, 10-45, 10-40, 10-35, 10-30, 10-25, 10-20, 10-15, 10-14, 10-13, 10-12 nucleotides, for example, about 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 nucleotides.

[0082] PCR amplification is a method well known in the art. Those skilled in the art can determine appropriate amplification steps and conditions based on the sequence to be amplified and the primer sequences.

[0083] In vitro transcription is a well-known method in the art. Those skilled in the art can determine appropriate transcription steps and conditions based on the sequence to be transcribed.

[0084] In a fifth aspect, the present invention provides a method for improving the efficiency of sgRNA-mediated gene editing, comprising adding a ribonucleotide sequence rich in adenine ribonucleotides (A) to the 3' end of the sgRNA, wherein the sgRNA and the ribonucleotide sequence rich in adenine ribonucleotides (A) are as described above.

[0085] Various methods are known in the art for adding ribonucleotide sequences to the 3' end of sgRNA, including chemical synthesis, recombinant methods, etc. In one embodiment, the addition of the desired ribonucleotide sequence to the 3' end of sgRNA is achieved by PCR amplification.

[0086] In a sixth aspect, the present invention provides a kit comprising:

[0087] - a template primer nucleic acid comprising a nucleic acid sequence encoding a CRISPR effector protein binding portion; and

[0088] - a first primer and a second primer, wherein the first primer comprises, from the 5' to the 3' direction, a sequence complementary to the sequence shown in SEQ ID NO: 13, 20 or 21 and a sequence complementary to a portion of the sequence at the 3' end of the template primer nucleic acid, and the second primer comprises, from the 5' to the 3' direction, a nucleotide sequence corresponding to a ribonucleotide sequence that specifically targets a target DNA sequence and a portion of the sequence at the 5' end of the template primer nucleic acid.

[0089] In one embodiment, the template primer nucleic acid comprises a polynucleotide having a sequence shown in SEQ ID NO:6.

[0090] In one embodiment, the first primer comprises a polynucleotide having a sequence shown in SEQ ID NO:5.

[0091] In one embodiment, the kit may further include, from the 5' to the 3' direction, a promoter sequence, a sequence encoding a ribonucleotide sequence that specifically targets the target DNA sequence, and a second primer encoding a portion of the sequence corresponding to the 5' end of the template primer nucleic acid. The promoter may be any suitable promoter known in the art, such as those that can be used for in vitro transcription, such as the T7 promoter. In one embodiment, the promoter comprises the sequence set forth in nucleotides 1-21 of SEQ ID NO:4.

[0092] In one embodiment, the kit may further include suitable reagents for in vitro transcription of DNA, such as RNA polymerase, and / or reagents for isolating and purifying RNA.

[0093] In one embodiment, the kit may further comprise a CRISPR effector protein as described herein.

[0094] In one embodiment, the kit can be used to prepare the RNA of the first aspect or the nucleic acid of the second aspect of the present invention, or for gene editing.

[0095] In a seventh aspect, the present invention provides a gene editing method comprising using the RNA of the first aspect, the nucleic acid of the second aspect, or the construct of the third aspect, for example, to introduce them into a target cell. Methods for introducing nucleic acids into target cells are well known in the art and include, for example, but not limited to, electroporation.

[0096] In an eighth aspect, the present invention provides use of the RNA of the first aspect, the nucleic acid of the second aspect, or the construct of the third aspect for gene editing.

[0097] The RNA or nucleic acid encoding the same according to the first aspect of the present invention can be used in gene editing. For example, the RNA of the present invention and a CRISPR effector protein, such as a Cas9 protein, are formed into a complex and then contacted with a target cell, thereby modifying the target DNA at the target DNA site, resulting in, for example, DNA cleavage, DNA methylation, DNA damage, DNA repair, etc.

[0098] Herein, the target cell can be any suitable cell that requires gene editing, including but not limited to cells of bacteria, archaea, plants, algae, fungi (such as yeast), animals such as non-human mammals such as rodents and humans.

[0099] The engineered sgRNA described in the present invention can improve genome editing efficiency and target specificity, regulate biological toxicity and editing flexibility, and achieve more specific, efficient, and safe gene editing, ultimately improving the clinical benefits of gene therapy.

[0100] As used herein, the word "or" is intended to include "and" unless the context indicates otherwise.

[0101] As used herein, "optional" or "optionally" means that the subsequently described event or circumstance occurs or does not occur, and the description includes instances where the event or circumstance occurs and instances where it does not occur. For example, an optionally included step means that the step exists or does not exist.

[0102] As used herein, the term "about" refers to a range of values ​​that includes the specific value and that one skilled in the art would reasonably consider to be similar to the specific value. In some embodiments, the term "about" refers to within the standard error of measurement using commonly accepted methods of measurement in the art. In some embodiments, about refers to ±10%, ±5%, ±4%, ±3%, ±2%, ±1%, or even ±0.5% of the specific value.

[0103] As used herein, when a specific value or ratio is listed for a feature in the specification, a range consisting of any two of the values ​​or ratios is also included. For example, when the values ​​1, 2, 3, and 4 are listed, a range of 1-2, 1-3, 1-4, 2-3, 2-4, and 3-4 is also included.

[0104] Although various embodiments and aspects of the present invention are shown and described herein, it will be apparent to those skilled in the art that these embodiments and aspects are merely examples of the present invention. Those skilled in the art can make various changes, alterations, and substitutions without departing from the spirit of the present invention. It will be appreciated that the various alternatives of the embodiments of the present invention described herein can be used in the enforcement of the present invention.

[0105] Example

[0106] The present invention will be further illustrated by the following non-limiting examples. It is well known to those skilled in the art that many modifications can be made to the present invention without departing from the spirit of the present invention, and such modifications also fall within the scope of the present invention.

[0107] Unless otherwise noted, the following experimental methods are conventional. The experimental materials used are readily available from commercial companies. Conventional plasmid construction experiments involving PCR, enzyme digestion, and ligation, as well as protein expression experiments involving transformation and bacterial culture, are familiar to researchers in the field. Therefore, specific experimental details are not provided. For details, please refer to the conventional experimental conditions described in the Molecular Cloning Manual [J. Sambrook et al., Molecular Cloning Manual (3rd Edition) [M], Science Press, 2002].

[0108] In addition to the specific methods, equipment, and materials used in the embodiments, based on the understanding of the prior art by those skilled in the art and the description of the present invention, any methods, equipment, and materials in the prior art that are similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention may also be used to implement the present invention.

[0109] Example 1: Preparation of sgRNA

[0110] Preparation method: First, DNA templates are quickly prepared by overlap extension polymerase chain reaction (PCR) and purified using a DNA purification kit. Then, sgRNA is prepared in large quantities by in vitro transcription. Finally, a large amount of sgRNA with high purity and integrity is obtained by purification (see Figure 1).

[0111] 1. PCR Assembly of DNA Templates for In Vitro Transcription

[0112] 1.1 Primers

[0113] 1.2 PCR reaction system: Add the reactants according to the table below, and the reaction system is 50 μl.

[0114] 1.3 PCR reaction procedure

[0115] 2. PCR product purification (common DNA product purification kit, brand: TIANGEN, product number: DP204)

[0116] This step was performed according to the instructions in the purification kit to purify and collect the DNA solution and detect the DNA concentration. This DNA solution was used as the template DNA for subsequent in vitro transcription.

[0117] 3. sgRNA in vitro transcription (Brand: Wuhan Hanhai Xinzyme Biotechnology Co., Ltd.)

[0118] sgRNA in vitro transcription: PCR reaction system configuration: Add each reactant according to the table below, the reaction system is 20μl

[0119] After reacting at 37°C for 4 h, 2 U of DNaseI (RNase-free) (brand: Wuhan Hanhai New Enzyme Biotechnology Co., Ltd., product number: HBP000907) was added to remove the DNA template at 37°C for 30 min.

[0120] 4. sgRNA Purification

[0121] 4.1 Add an equal volume of 5 M LiCl solution (Brand: Wuhan Hanhai New Enzyme Biotechnology Co., Ltd., Batch No.: HH20221020) to the in vitro transcription (IVT) product, mix well, and place at -20°C for at least 30 min.

[0122] 4.2 Centrifuge at 12500g for 15 min at 4°C.

[0123] 4.3 Discard the supernatant and add 10 times the volume of pre-cooled 70% ethanol to wash the RNA precipitate. Centrifuge at 4℃ for 8 minutes.

[0124] 4.4 Discard the supernatant and add 10 times the volume of pre-cooled 70% ethanol to wash the RNA precipitate. Centrifuge at 4℃ for 8 minutes.

[0125] 4.5 Dissolve the RNA pellet with an appropriate volume of RNase-free H2O.

[0126] 4.6 Detection concentration.

[0127] Example 2: Verification of extracellular function of sgRNA

[0128] 1. Cell Culture

[0129] 1.1 Turn on the UV light of the biosafety cabinet for disinfection half an hour in advance. Preheat DMEM complete medium in a 37°C water bath. Keep DPBS (Brand: BBI, Catalog No.: E607009-0500) and Tryple (Brand: Gibco, Catalog No.: A12859-01) at room temperature.

[0130] 1.2 After disinfection, remove the cell culture dish from the 5% CO2 incubator, discard the supernatant in the cell culture dish, add 1 ml of DPBS, and gently shake to wash and remove the residual culture medium.

[0131] 1.3 Aspirate and discard DPBS, add 1 ml of Tryple to the cell culture dish, let it stand for 1 min, add 2 ml of DMEM complete medium, gently blow off the 293T cells at the bottom of the cell culture dish, aspirate all the cells and transfer them to a 50 ml centrifuge tube, mark it as 293T, and gently pipette to mix.

[0132] 1.4 Aspirate the cell suspension and add it to a 1.5ml EP tube for DNA extraction. If genomic extraction cannot be performed immediately, centrifuge at 300g for 3 minutes, remove the supernatant, and store the cell pellet at -20°C.

[0133] 2. Cell genome extraction (AxyPrep Genomic DNA Mini Kit, Brand: AXYGEN, Catalog Number: AP-MN-MS-GDNA-4AP-MN-MS-GDNA-50)

[0134] This step was performed according to the instructions in the purification kit to purify and collect DNA, which was stored at -20°C for subsequent PCR identification.

[0135] 3. Target gene amplification

[0136] 3.1 PCR verification was performed using primers Primer 1F / 1R and the cell genome.

[0137] 3.2 The PCR reaction kit was: Novagen 2× Taq Plus Master Mix II (Dye Plus).

[0138] 3.3 Preparation of PCR reaction system:

[0139] 3.4 The PCR reaction procedure is as follows:

[0140] 3.5 Preparation of agarose gel: Weigh 0.3 g agarose (Brand: Biotium, Catalog No.: 9012-36-6) and add it to 30 ml TAE (1×) (Brand: Biotium, Catalog No.: B548101-0500). Melt it by microwave heating. Add 3 μl GelRed (Brand: Biotium, Catalog No.: 41003), mix well, pour it into a gel plate, and wait for it to cool and solidify.

[0141] 3.6 After the PCR reaction is completed, take 5 μl of PCR product and perform agarose gel electrophoresis to observe whether the band size is consistent with the target band size. If the band size is consistent with the expected size, the PCR product is purified.

[0142] 4. Purification of target gene (common DNA product purification kit, brand: TIANGEN, product number: DP204)

[0143] This step was performed according to the instructions in the purification kit to purify the collected DNA solution and detect the DNA concentration.

[0144] 5. In vitro enzyme cleavage function verification

[0145] 5.1 Formation of sgRNA and Cas9 protein complex: In a clean 200 μl PCR tube, add ultrapure water (to make up the digestion volume to 30 μl), 10 μmol Cas9 protein, and 10 μmol gRNA. Mix thoroughly. Add 3 μl of 10× buffer. Incubate at room temperature for 10 minutes to allow RNP formation.

[0146] 5.2 Add 1 μmol DNA and incubate at 37°C for 25 minutes. After incubation, add 0.5 μl RNase A, mix well, and then add 3 μl Protein K. Incubate at 56°C for 10 minutes to digest the Cas9 protein.

[0147] 5.3 Preparation of agarose gel: Weigh 0.6 g agarose, add it to 60 ml TAE (1×), melt it by microwave heating, add 6 μl GelRed, mix well, pour it into a gel plate, and wait for it to cool and solidify.

[0148] 5.4 Take out the enzyme digestion product and perform agarose gel electrophoresis together with the negative control. Take 15 μl for electrophoresis.

[0149] 6. Results

[0150] As shown in Figures 2 and 3, the in vitro results showed that the unengineered sgRNA (SEQ ID NO: 1, 101 nt), the engineered sgRNA (SEQ ID NO: 2, 126 nt) and the chemically synthesized base-modified sgRNA (SEQ ID NO: 3, 101 nt) can all effectively guide the cas9 protein to cut the target DNA.

[0151] Example 3: Functional Verification of sgRNA in iPSC Cells

[0152] 1. Cell Culture

[0153] 1.1 Turn on the UV light of the biosafety cabinet for disinfection half an hour in advance, and preheat Y27632 (Brand: MCE, Product No.: HY-10583) + ncTarget complete medium (Brand: Zhongsheng Suyuan Biotechnology Co., Ltd., Product No.: RP01020), DPBS and EDTA passaging working solution (Brand: Zhongsheng Suyuan Biotechnology Co., Ltd., Product No.: RP01007) at room temperature.

[0154] 1.2 After disinfection, remove the cell culture dish from the 5% CO2 incubator, discard the supernatant in the cell culture dish, add 1 ml of DPBS, and gently shake to wash and remove the residual culture medium.

[0155] 1.3 Aspirate and discard DPBS, add 1 ml of EDTA passaging solution to the cell culture dish, let it stand for 5-8 minutes, then aspirate and discard. Add 2 ml of Y27632+ncTarget complete medium, gently blow off the iPSCs cells at the bottom of the cell culture dish, aspirate all the cells and transfer them to a 50 ml centrifuge tube, label it as iPSCs, gently pipette to mix, and centrifuge at 300g for 3 minutes. Aspirate the supernatant and set the cells aside.

[0156] 2. Cell Electroporation

[0157] 2.1 Prepare a cell suspension of iPSCs by gently pipetting to reduce them to single cells and counting them using a cell counter. (TrypLE can be used to digest the cells, but pay attention to the digestion time, which should be 1-2 minutes.)

[0158] 2.2 In advance, mix the electroporation buffer A (Celetrix) and buffer B (Celetrix) at a ratio of 1:1 and mark it as buffer C for later use.

[0159] 2.3 Add 1-1.5 μg Cas9 protein, 1-1.5 μg sgRNA, 2 μg donor DNA, and 10 μL buffer C to a 1.5 mL EP centrifuge tube and incubate at room temperature for 10-15 minutes.

[0160] 2.4 Harvest 1-1.5×10 6 The living cells were collected by centrifugation at 200 g for 3 min.

[0161] 2.5 Resuspend the cell pellet from step 2.4 in 10 μL buffer C.

[0162] 2.6 Gently mix the solutions from steps 2.3 and 2.5 and incubate at room temperature for 10 min.

[0163] 2.7 Perform electroporation on the cells according to the instructions of the Celetrix electroporator. iPSC cells can be electroporated at 540V.

[0164] 2.8 After electroporation, gently transfer the cells to a culture plate containing pre-warmed Y27632+ncTarget complete medium.

[0165] 2.9 Shake the cells horizontally in a cross-section, place in a 37°C, 5% CO2 incubator, shake again horizontally in a cross-section, and incubate overnight. After 18-24 hours, replace with fresh ncTarget complete medium, and change the medium daily thereafter.

[0166] 3. Cell genome extraction (AxyPrep Genomic DNA Mini Kit, Brand: AXYGEN, Catalog Number: AP-MN-MS-GDNA-4AP-MN-MS-GDNA-50)

[0167] This step was performed according to the instructions in the purification kit to purify and collect DNA, which was then stored at -20°C for subsequent homologous recombination efficiency assessment.

[0168] 4. Target gene amplification and identification of successful homologous recombination

[0169] 4.1 PCR verification was performed using primers on both sides of the homologous arms after homologous recombination and the cell genome.

[0170] 4.2 The PCR reaction kit was: Novagen 2× Taq Plus Master Mix II (Dye Plus).

[0171] 4.3 Preparation of left homology arm PCR reaction system:

[0172] 4.4 Preparation of right homology arm PCR reaction system:

[0173] 4.5 The PCR reaction procedure is as follows:

[0174] 4.6 Agarose gel preparation: Weigh 0.3 g agarose, add to 30 ml TAE (1×), microwave heating to melt, add 3 μl GelRed, mix well, pour into a gel plate, and wait for cooling to solidify.

[0175] 4.7 After the PCR reaction is completed, take 5 μl of the PCR product and perform agarose gel electrophoresis to observe whether the band size matches the target band size. If the band size meets the expected size, purify the PCR product.

[0176] 5. Results

[0177] In vitro gene editing results showed that the unengineered sgRNA (SEQ ID NO: 1), the engineered sgRNA (SEQ ID NO: 2), and the chemically synthesized base-modified sgRNA (SEQ ID NO: 3) could all effectively guide the Cas9 protein to cleave the target DNA (Figures 2 and 3).

[0178] In vivo homologous recombination results showed that compared with unengineered sgRNA, engineered sgRNAs (co-modified with capping enzyme and tailing enzyme, fixed sequence modification, co-modified with capping enzyme and fixed sequence, and chemically synthesized base modification) could all efficiently guide DNA templates for homologous recombination (Figure 4A, comparison of the results in lanes 3, 4, 5, 6 and lane 2; Figure 4B, comparison of the results in lanes 3, 4, 5, 6 and lane 2). Among them, compared with other engineered sgRNAs (co-modified with capping enzyme and tailing enzyme, co-modified with capping enzyme and fixed sequence, and chemically synthesized base modification), sgRNAs with added sequences at the 3' end showed the same effect and efficiency in guiding DNA templates for homologous recombination (Figure 4A, comparison of the results in lanes 3, 5, 6 and lane 4; Figure 4B, comparison of the results in lanes 3, 5, 6 and lane 4).

[0179] Therefore, compared with sgRNA engineered by other methods, sgRNA with a single fixed sequence modification at the 3' end has obvious advantages such as low cost, simple process, and easy large-scale production, providing sufficient guarantee and support for new gene editing therapies.

[0180] Example 4: Effect of the length of the 3-terminal added sequence on the intracellular function of sgRNA

[0181] 1. Cell Culture

[0182] 1.1 Adherent culture A 293T cell line (293T-GL) that has been stably transformed with the NeonGreen-teLuciferase expression element (Zhang Y, Hu J, Yu M, Wang Z, Qing H, Fu H, Yuan L, Li F, Zhao S*. A novel BRET based genetically coded biosensor for apoptosis detection at deep tissue level in live animal. Apoptosis. 2021 Dec; 26(11-12): 628-638. doi: 10.1007 / s10495-021-01693-x. Epub 2021 Nov 8.) was used to express green fluorescent protein and teLuciferase.

[0183] 1.3 Aspirate and discard DPBS, add 1 ml of Tryple to the cell culture dish, let it stand for 1 min, add 2 ml of DMEM complete medium, gently blow off the 293T cells at the bottom of the cell culture dish, aspirate all the cells and transfer them to a 50 ml centrifuge tube, mark it as 293T, gently pipette to mix, centrifuge at 300g for 3 min, aspirate the supernatant and set the cells aside.

[0184] 2. Cell Electroporation

[0185] 2.1 Prepare a cell suspension of 293T-GL cells by gently pipetting to reduce them to single cells and counting them using a cell counter. (You can also use TrypLE to digest the cells, but pay attention to the digestion time, 1-2 minutes is sufficient)

[0186] 2.2 In advance, mix the electroporation buffer A (Celetrix) and buffer B (Celetrix) at a ratio of 1:1 and mark it as buffer C for later use.

[0187] 2.3 Add 1-1.5 μg of Cas9 protein, 1-1.5 μg of sgRNA targeting the NeonGreen coding region with different lengths of 3'-end added sequences: NG0-sgRNA, SEQ ID NO: 14; NG5-sgRNA, SEQ ID NO: 15; NG10-sgRNA, SEQ ID NO: 16; NG15-sgRNA, SEQ ID NO: 17; NG20-sgRNA, SEQ ID NO: 18; or NG25-sgRNA, SEQ ID NO: 19 (the lengths of the 3'-end added sequences of these sgRNAs are 0, 5, 10, 15, 20, and 25 nucleotide residues, respectively), 2 μg of donor DNA, and 10 μL of buffer C to a 1.5 mL EP centrifuge tube and incubate at room temperature for 10-15 min.

[0188] 2.4 Harvest 1-1.5×10 6 The living cells were collected by centrifugation at 200 g for 3 min.

[0189] 2.5 Resuspend the cell pellet from step 2.4 in 10 μL buffer C.

[0190] 2.6 Gently mix the solutions from steps 2.3 and 2.5 and incubate at room temperature for 10 min.

[0191] 2.7 Perform electroporation of cells at 540V according to the instructions of the Celetrix electroporator.

[0192] 2.8 After electroporation, gently transfer the cells to a culture plate containing pre-warmed DMEM complete medium.

[0193] 2.9 Shake the cells horizontally in a cross-section, place in a 37°C, 5% CO2 incubator, shake again horizontally in a cross-section, and incubate overnight. Replace the culture medium with fresh DMEM complete medium after 18-24 hours, and change the medium daily thereafter.

[0194] 3. Luciferase Activity Test

[0195] After one week of electroporation, the cells were digested and 3 replicates (5x10 4 Cells were placed in a 96-well plate and lysed with 10 μl of 10% triton X100 at room temperature for 5 minutes. Luciferase activity was then quantitatively measured using a fluorescence microplate reader and the luciferase substrate, diphenylterazine (DTZ, final concentration 30 μM). Luminescence intensity was measured after mixing by shaking for 5 seconds.

[0196] 4. Results

[0197] After successful gene editing, the NeonGreen-teLuciferase expression element in the stable cell line 293T-GL, which originally expressed NeonGreen-teLuciferase, was replaced by editing, and luciferase was no longer expressed. The previously expressed luciferase protein also gradually decreased to background levels within one week. Therefore, by measuring the residual luciferase activity one week after gene editing, the relative efficiency of gene editing mediated by different sgRNAs can be compared. The results in Figure 5 show that the added sequence at the 3' end with 20 / 25 nucleotide residues is significantly more effective than shorter sequences, with the NG20-sgRNA having the best effect.

[0198] Sequence Listing

Claims

1. A DNA-targeting RNA comprising, from 5' to 3' direction: (i) single guide RNA (sgRNA); and (ii) a ribonucleotide sequence rich in adenine ribonucleotides (A), the length of the ribonucleotide sequence being at least 20 ribonucleotides, preferably 20-30, more preferably 20-25 ribonucleotides, wherein the content of A in the ribonucleotide sequence is at least 60%, preferably at least 70%, at least 75% or more, in particular, the ribonucleotide sequence is selected from the nucleotide sequences shown in SEQ ID NOs: 13, 20 and 21, Preferably, the DNA is present in a unicellular eukaryote, a plant cell, an invertebrate cell or a vertebrate cell.

2. The DNA-targeting RNA of claim 1, wherein the sgRNA comprises, from 5' to 3' direction: - a ribonucleotide sequence that specifically targets a DNA sequence, preferably, the ribonucleotide sequence is 18-25 ribonucleotides in length and is preferably 100% complementary to the target sequence in the DNA, and -CRISPR effector protein binding part, Preferably, the CRISPR effector protein is selected from Cas3, Cas8a, Cas5, Cas8b, Cas8c, Cas10d, Cse1, Cse2, Csy1, Csy2, Csy3, GSU0054, Cas10, Csm2, Cmr5, Cas10, Csx11, Csx10, Csf1, Cas9, Csn2, Cas4, Cpf1, C2c1, C2c3 or C2c2 protein, or functional variants of these nucleases.

3. An isolated nucleic acid comprising a nucleotide sequence encoding the DNA-targeting RNA of claim 1 or 2, optionally further comprising a promoter operably linked to the nucleotide sequence.

4. The nucleic acid of claim 3, comprising a polynucleotide encoding a promoter, sgRNA and the adenine ribonucleotide-rich ribonucleotide sequence, preferably, the promoter is a T7 promoter, for example, comprising the sequence shown in nucleotides 1 to 21 of SEQ ID NO:

4.

5. A construct, such as an expression vector, comprising the nucleic acid of claim 3 or 4.

6. A method for preparing the DNA-targeting RNA of claim 1 or 2, comprising: (a) providing a nucleic acid encoding the DNA-targeting RNA, such as the nucleic acid of claim 3 or 4, and (b) transcribing the nucleic acid in vitro to produce RNA, and (c) optionally isolating and purifying the produced RNA.

7. The method of claim 6, wherein the nucleic acid is obtained by PCR amplification, preferably, the (a) comprises: (i) providing a template primer nucleic acid comprising a portion encoding a CRISPR effector protein binding moiety, preferably the template primer nucleic acid comprises a DNA sequence as shown in SEQ ID NO: 6, (ii) providing an upstream primer and a downstream primer, wherein the downstream primer comprises, from the 5' to the 3' direction, a sequence complementary to the nucleotide sequence of the nucleic acid shown in SEQ ID NO: 13, 20 or 21 and a portion complementary to the 3' end of the template primer nucleic acid; The upstream primer comprises a nucleotide sequence corresponding to a ribonucleotide sequence specifically targeting a target DNA sequence and a partial sequence at the 5' end of the template primer nucleic acid from the 5' to 3' direction, Preferably, the downstream primer comprises the DNA sequence shown in SEQ ID NO: 5, and (iii) performing PCR amplification to obtain a template nucleic acid, preferably a template DNA.

8. A method for improving the efficiency of sgRNA-mediated gene editing, comprising adding a ribonucleotide sequence rich in adenine ribonucleotides (A) to the 3' end of the sgRNA, wherein the length of the ribonucleotide sequence is at least 20 ribonucleotides, preferably 20-30, more preferably 20-25 ribonucleotides, wherein the content of A in the ribonucleotide sequence is at least 60%, preferably 70%, at least 75%, at least 80%, at least 90% or more, in particular, the ribonucleotide sequence is selected from: SEQ ID NO: 13, 20 and 21.

9. The method of claim 8, wherein the sgRNA comprises from 5' to 3' direction: - a ribonucleotide sequence that specifically targets a DNA sequence, and -CRISPR effector protein binding moiety.

10. A kit comprising: - a template primer nucleic acid comprising a nucleic acid sequence encoding a CRISPR effector protein binding moiety, wherein the CRISPR effector protein binding moiety comprises crRNA and tracrRNA from 5' to 3' direction, optionally comprising a tetraloop region; and - A first primer comprising, from 5' to 3' direction, a sequence complementary to the sequence shown in SEQ ID NO: 13, 20 or 21 and a sequence complementary to a portion of the sequence at the 3' end of the template primer nucleic acid.

11. The kit of claim 10, wherein: (a) the first primer comprises a polynucleotide having a sequence as shown in SEQ ID NO: 5; and / or (b) the template primer nucleic acid comprises a polynucleotide having a sequence as shown in SEQ ID NO: 6; and / or (c) The kit further comprises a second primer comprising, from 5' to 3' direction, a promoter sequence, a sequence corresponding to a ribonucleotide sequence of a specific targeting DNA sequence, and a sequence corresponding to a partial sequence at the 5' end of the template primer nucleic acid. Preferably, the promoter is a T7 promoter, for example, comprising the sequence shown in nucleotides 1 to 21 of SEQ ID NO:

4.

12. A gene editing method, comprising the step of introducing the DNA-targeting RNA of claim 1 or 2, the nucleic acid of claim 3 or 4, or the construct of claim 5, and optionally a CRISPR effector protein into a target cell.

13. Use of the DNA-targeting RNA of claim 1 or 2, the nucleic acid of claim 3 or 4, or the construct of claim 5 in gene editing.

Citation Information

Patent Citations

  • Regulator of calcineurin 1 (RCAN1) aptamer RCAN1-s14

    CN108384787A

  • Oligonucleotides for modulating SCN9a expression

    CN112513273A

  • Crispr / CAS systems for genomic modification and gene modulation

    US20140273226A1